Protalix BioTherapeutics (PLX) is scheduled to report Q1 earnings on May 8, 2026. Analysts estimate EPS of $-0.01 and quarterly revenue of $11.47M.

In the most recent quarter (Q4), Protalix BioTherapeutics reported EPS of $-0.06, missing estimates of $0.01 by 7.00%. Revenue came in at $9.30M, missing the estimate of $14.36M by 0.35%.

Protalix BioTherapeutics has missed EPS estimates in 4 consecutive quarters.

Over the last 4 quarters, Protalix BioTherapeutics has averaged an EPS surprise of 2.51% and a revenue surprise of 0.26%.